Citigroup
ADMS

Citigroup’s Adamas Pharmaceuticals ADMS Stock Holding History

Citigroup’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,000
Closed -$43K – 7784
2020
Q4 		$43K Hold
10,000
– – ﹤0.01% 6160
2020
Q3 		$41K Buy
+10,000
New +$38.7K ﹤0.01% 5728
2020
Q2 		– Sell
-7,091
Closed -$20K – 7761
2020
Q1 		$20K Sell
7,091
-15,188
-68% -$68.1K ﹤0.01% 6709
2019
Q4 		$84K Buy
22,279
+3,938
+21% +$18.9K ﹤0.01% 5920
2019
Q3 		$94K Sell
18,341
-192
-1% -$1.19K ﹤0.01% 5720
2019
Q2 		$115K Buy
18,533
+841
+5% +$4.84K ﹤0.01% 5742
2019
Q1 		$126K Sell
17,692
-155,487
-90% -$1.4M ﹤0.01% 5536
2018
Q4 		$1.48M Buy
173,179
+72,701
+72% +$945K ﹤0.01% 2976
2018
Q3 		$2.01M Buy
100,478
+33,366
+50% +$783K ﹤0.01% 2743
2018
Q2 		$1.73M Sell
67,112
-28,190
-30% -$781K ﹤0.01% 2805
2018
Q1 		$2.28M Sell
95,302
-45,347
-32% -$1.43M ﹤0.01% 2492
2017
Q4 		$4.77M Buy
140,649
+120,200
+588% +$3.36M ﹤0.01% 1881
2017
Q3 		$433K Buy
20,449
+20,351
+20,766% +$373K ﹤0.01% 4263
2017
Q2 		$2K Buy
98
+97
+9,700% +$1.6K ﹤0.01% 7060
2017
Q1 		$0 Buy
+1
New +$17 ﹤0.01% 7404
2016
Q4 		– Sell
-299
Closed -$5K – 7386
2016
Q3 		$5K Sell
299
-3,256
-92% -$49.5K ﹤0.01% 6793
2016
Q2 		$54K Sell
3,555
-10,596
-75% -$175K ﹤0.01% 5529
2016
Q1 		$204K Buy
14,151
+7,345
+108% +$124K ﹤0.01% 5077
2015
Q4 		$193K Buy
6,806
+6,066
+820% +$102K ﹤0.01% 4785
2015
Q3 		$12K Sell
740
-4,451
-86% -$101K ﹤0.01% 6347
2015
Q2 		$136K Buy
5,191
+3,402
+190% +$66.2K ﹤0.01% 4759
2015
Q1 		$31K Buy
1,789
+298
+20% +$5.11K ﹤0.01% 5826
2014
Q4 		$26K Buy
1,491
+1,387
+1,334% +$21K ﹤0.01% 6094
2014
Q3 		$2K Buy
104
+40
+63% +$688 ﹤0.01% 6834
2014
Q2 		$1K Buy
+64
New +$1.15K ﹤0.01% 6994

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return

Citigroup's ADMS Position: Q1 2021 in Review

Citigroup sold out of Adamas Pharmaceuticals (ADMS) in Q1 2021, closing a stake of 10,000 shares — an estimated $43K sold.

Citigroup first reported a position in ADMS in Q2 2014 and held it in 25 quarters. The position peaked at $4.77M in Q4 2017. 73 funds tracked by Wall St. Rank hold ADMS as of Q1 2021.

  • Citigroup reported no remaining Adamas Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Citigroup sold 10,000 Adamas Pharmaceuticals shares in Q1 2021, an estimated $43K.
  • Citigroup first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 25 quarters.
  • Citigroup's Adamas Pharmaceuticals position peaked at $4.77M in Q4 2017.
  • 73 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2021.

Based on Citigroup's 13F filing for Q1 2021, filed 13 May 2021.